No record found
No record found
No record found
capitalstake.com. Provided by * Returns not adjusted for payouts
^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.
Company Profile
Liven Pharma Limited was incorporated in Pakistan as a private Limited Company on October 21, 1991 and was converted into a public limited company on April 30, 1992 under the Companies Ordinance, 1984 (Repealed with the enactment of the Companies Act, 2017). The principal activity of the Company is the manufacturing of pharmaceuticals and allied products.
| Kashif Hussain Siddiquie | CEO |
| Atif Hussain Siddiqi | Chairman |
| Muhammad Saeed | Company Secretary |
F.D. Registrar Services SMC (Pvt.) Ltd., 1705,17th Floor, Saima Trade Tower A, I.I. Chundrigar Road, Karachi
M/s Reanda Haroon Zakaria Aamir Salman Rizwan & Company, Chartered Accountants
June
Equity Profile
Announcements
| Date | Title | Document |
|---|---|---|
| Oct 5, 2026 | financial results for the Year Ended June 30, 2026 | View PDF |
| Oct 5, 2026 | Transmission of Annual Report for the Year Ended June 30, 2026 | View PDF |
| Apr 29, 2026 | Financial Results for the 3rd Quarter Ended 31st March 2026 | View PDF |
| Mar 9, 2026 | Condensed Interim Financial Statements for the Half Year ended December 31, 2025 (with shariah compliant disclosure) | View PDF |
| Feb 27, 2026 | Condensed Interim Financial Statements for the Half Year ended December 31, 2025. | View PDF |
| Date | Title | Document |
|---|---|---|
| Oct 5, 2026 | Correction Clarification Regarding Annual Report 2026 | View PDF |
| Aug 27, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Jul 15, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Jul 14, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Jul 14, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Financials
All numbers in thousands (000's) except EPS
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Sales | 105,807 | 127,272 | 245,093 | |
| Profit after Taxation | (31,139) | (584,460) | 41,744 | (12,327) |
| EPS | (0.28) | (7.11) | 1.04 | (1.02) |
| Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | |
|---|---|---|---|---|
| Sales | 29,247 | 54,559 | 8,821 | 14,755 |
| Profit after Taxation | (3,956) | 28,210 | (30,157) | (9,621) |
| EPS | (0.03) | (0.30) | (0.32) | (0.10) |

Ratios
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Gross Profit Margin (%) | 25.18 | 14.11 | 25.46 | |
| Net Profit Margin (%) | (29.43) | (459.22) | 17.03 | |
| EPS Growth (%) | 96.06 | (781.03) | 202.35 | 13.56 |
| PEG | (1.51) | 0.01 | 0.04 | (1.06) |









Feedback
Terms of Use
https://www.psx.com.pk